StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.18+0.02 (+0.93%)

Close on Nov 18, 2026Market cap $104.09MP/E –Yield –

Minerva Neurosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Minerva Neurosciences's revenue for the twelve months ending Dec 31, 2021 was $0, down 100.0% year over year. For fiscal 2024 it was $0. The highest annual figure on record is $41.18M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$0–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$41.18M–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0-100.0%
Q1 FY2021Mar 31, 2021$0–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$41.18M–
Q1 FY2020Mar 31, 2020$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–

More Minerva Neurosciences figures

See a number that looks wrong?